Handel Amgen - AMGN CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.77 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
Gebyr natten over, tid | 22:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Amgen Inc ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Tidligere luk* | 244.57 |
Åben* | 244.61 |
1-Års Ændring* | 9.95% |
Dagens Spænd* | 243.24 - 244.93 |
52-Ugers Spænd | 214.39-296.67 |
Gennemsnitlig Volumen (10 dage) | 2.95M |
Gennemsnitlig Volumen (3 måneder) | 55.89M |
Market Cap | 130.92B |
P/E-forhold | 20.24 |
Udestående aktier | 534.00M |
Omsætning | 26.32B |
EPS | 12.11 |
Dividend (Udbytte %) | 3.47514 |
Beta | 0.63 |
Næste indtjeningsopgørelse | Feb 6, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 244.57 | -3.44 | -1.39% | 248.01 | 249.24 | 241.75 |
Feb 2, 2023 | 245.61 | 2.54 | 1.04% | 243.07 | 246.19 | 235.61 |
Feb 1, 2023 | 245.85 | -2.80 | -1.13% | 248.65 | 248.87 | 239.66 |
Jan 31, 2023 | 251.50 | 0.06 | 0.02% | 251.44 | 252.27 | 249.46 |
Jan 30, 2023 | 251.22 | -0.27 | -0.11% | 251.49 | 253.64 | 250.16 |
Jan 27, 2023 | 253.18 | -1.00 | -0.39% | 254.18 | 254.78 | 252.16 |
Jan 26, 2023 | 254.36 | -0.58 | -0.23% | 254.94 | 256.12 | 252.57 |
Jan 25, 2023 | 256.02 | -3.70 | -1.42% | 259.72 | 261.13 | 255.52 |
Jan 24, 2023 | 259.11 | -0.41 | -0.16% | 259.52 | 261.45 | 256.93 |
Jan 23, 2023 | 260.45 | -2.68 | -1.02% | 263.13 | 264.27 | 259.31 |
Jan 20, 2023 | 262.82 | 3.73 | 1.44% | 259.09 | 263.44 | 258.02 |
Jan 19, 2023 | 261.49 | 0.26 | 0.10% | 261.23 | 263.11 | 260.31 |
Jan 18, 2023 | 263.82 | -5.06 | -1.88% | 268.88 | 269.60 | 262.76 |
Jan 17, 2023 | 268.83 | -1.89 | -0.70% | 270.72 | 273.40 | 268.32 |
Jan 13, 2023 | 271.36 | 2.20 | 0.82% | 269.16 | 271.74 | 269.16 |
Jan 12, 2023 | 270.44 | 0.00 | 0.00% | 270.44 | 271.57 | 268.00 |
Jan 11, 2023 | 272.26 | -2.85 | -1.04% | 275.11 | 275.97 | 269.55 |
Jan 10, 2023 | 273.41 | 4.07 | 1.51% | 269.34 | 274.15 | 268.61 |
Jan 9, 2023 | 269.67 | -3.70 | -1.35% | 273.37 | 274.39 | 268.16 |
Jan 6, 2023 | 274.64 | 7.41 | 2.77% | 267.23 | 276.36 | 267.23 |
Amgen Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total omsætning | 22991 | 22849 | 23747 | 23362 | 25424 | 25979 |
Omsætning | 22991 | 22849 | 23747 | 23362 | 25424 | 25979 |
Kost af omsætning, Total | 4162 | 4069 | 4101 | 4356 | 6159 | 6454 |
Bruttofortjeneste | 18829 | 18780 | 19646 | 19006 | 19265 | 19525 |
Totale Driftsudgifter | 13197 | 12876 | 13404 | 13688 | 16285 | 18340 |
Salgs/Generelle/Admin. Udgifter, Total | 5062 | 4870 | 5332 | 5150 | 5730 | 6873 |
Forskning & Udvikling | 3840 | 3562 | 3737 | 4116 | 4207 | 4819 |
Usædvanlig Udgift (Indkomst) | -6 | 367 | 292 | 47 | ||
Other Operating Expenses, Total | 139 | 8 | -58 | 19 | 189 | 194 |
Driftsindtægter | 9794 | 9973 | 10343 | 9674 | 9139 | 7639 |
Renteindkomst (Udgift), Netto Ikke-Drift | -631 | -376 | -798 | -536 | -1006 | -1197 |
Netto Indkomst Før Skat | 9163 | 9597 | 9545 | 9138 | 8133 | 6701 |
Netto Indkomst Efter Skat | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Netto Indkomst Før Ekstra Ting | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Netto Indkomst | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 7722 | 8079 | 8394 | 7842 | 7264 | 5893 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Fortyndet Netto Indkomst | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Fortyndet Vægtet Gennemsnit Aktier | 754 | 735 | 665 | 609 | 590 | 573 |
Fortyndet EPS Uden Ekstraordinære Ting | 10.2414 | 10.9918 | 12.6226 | 12.8769 | 12.3119 | 10.2845 |
Dividends per Share - Common Stock Primary Issue | 4 | 4.6 | 5.28 | 5.8 | 6.4 | 7.04 |
Fortyndet Normaliseret EPS | 10.2347 | 11.4122 | 13.0087 | 12.9431 | 12.3119 | 10.2845 |
Totale Ekstraordinære Ting | -6100 | |||||
Andre, Netto | 259 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total omsætning | 5901 | 6526 | 6706 | 6846 | 6238 |
Omsætning | 5901 | 6526 | 6706 | 6846 | 6238 |
Kost af omsætning, Total | 1490 | 1637 | 1609 | 1718 | 1561 |
Bruttofortjeneste | 4411 | 4889 | 5097 | 5128 | 4677 |
Totale Driftsudgifter | 3772 | 5698 | 4328 | 4542 | 3738 |
Salgs/Generelle/Admin. Udgifter, Total | 1254 | 2889 | 1305 | 1425 | 1228 |
Forskning & Udvikling | 967 | 1082 | 1422 | 1348 | 959 |
Other Operating Expenses, Total | 61 | 90 | -8 | 51 | -10 |
Driftsindtægter | 2129 | 828 | 2378 | 2304 | 2500 |
Renteindkomst (Udgift), Netto Ikke-Drift | -285 | -281 | -296 | -335 | -295 |
Andre, Netto | 13 | 11 | 73 | 162 | -530 |
Netto Indkomst Før Skat | 1857 | 558 | 2155 | 2131 | 1675 |
Netto Indkomst Efter Skat | 1646 | 464 | 1884 | 1899 | 1476 |
Netto Indkomst Før Ekstra Ting | 1646 | 464 | 1884 | 1899 | 1476 |
Netto Indkomst | 1646 | 464 | 1884 | 1899 | 1476 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 1646 | 464 | 1884 | 1899 | 1476 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 1646 | 464 | 1884 | 1899 | 1476 |
Fortyndet Netto Indkomst | 1646 | 464 | 1884 | 1899 | 1476 |
Fortyndet Vægtet Gennemsnit Aktier | 581 | 576 | 570 | 564 | 551 |
Fortyndet EPS Uden Ekstraordinære Ting | 2.83305 | 0.80556 | 3.30526 | 3.36702 | 2.67877 |
Dividends per Share - Common Stock Primary Issue | 1.76 | 1.76 | 1.76 | 1.76 | 1.94 |
Fortyndet Normaliseret EPS | 2.83305 | 0.80556 | 3.30526 | 3.36702 | 2.67877 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale Nuværende Aktiver | 46010 | 49476 | 37618 | 18440 | 21144 | 19385 |
Likvider og Kortsigtede Investeringer | 38085 | 41678 | 29304 | 8911 | 10647 | 8037 |
Likvider & Lignende | 3241 | 3800 | 6945 | 6037 | 6266 | 7989 |
Kortsigtede Investeringer | 34844 | 37878 | 22359 | 2874 | 4381 | 48 |
Totale Tilgodehavender, Netto | 3165 | 3237 | 3580 | 4057 | 5324 | 5839 |
Accounts Receivable - Trade, Net | 3165 | 3237 | 3580 | 4057 | 4525 | 4895 |
Total Inventory | 2745 | 2834 | 2940 | 3584 | 3893 | 4086 |
Other Current Assets, Total | 2015 | 1727 | 1794 | 1888 | 124 | 200 |
Total Assets | 77626 | 79954 | 66416 | 59707 | 62948 | 61165 |
Property/Plant/Equipment, Total - Net | 4961 | 4989 | 4958 | 5397 | 5297 | 5750 |
Property/Plant/Equipment, Total - Gross | 12427 | 12579 | 12754 | 13754 | 14274 | 14548 |
Accumulated Depreciation, Total | -7466 | -7590 | -7796 | -8357 | -8977 | -8798 |
Goodwill, Net | 14751 | 14761 | 14699 | 14703 | 14689 | 14890 |
Intangibles, Net | 10279 | 8609 | 7443 | 19413 | 16587 | 15182 |
Long Term Investments | 501 | 570 | 1176 | 573 | ||
Other Long Term Assets, Total | 1124 | 1549 | 1698 | 1754 | 4055 | 5385 |
Total Current Liabilities | 11204 | 9020 | 13488 | 12835 | 11653 | 12184 |
Accounts Payable | 917 | 1352 | 1207 | 1371 | 1421 | 1366 |
Accrued Expenses | 4964 | 5563 | 6948 | 7565 | 8295 | 8947 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4403 | 1152 | 4419 | 2953 | 91 | 87 |
Other Current Liabilities, Total | 920 | 953 | 914 | 946 | 1846 | 1784 |
Total Liabilities | 47751 | 54713 | 53916 | 50034 | 53539 | 54465 |
Total Long Term Debt | 30193 | 34190 | 29510 | 26950 | 32895 | 33222 |
Long Term Debt | 30193 | 34190 | 29510 | 26950 | 32895 | 33222 |
Deferred Income Tax | 2436 | 1166 | 864 | 606 | ||
Other Liabilities, Total | 3918 | 10337 | 10054 | 9643 | 8991 | 9059 |
Total Equity | 29875 | 25241 | 12500 | 9673 | 9409 | 6700 |
Common Stock | 30784 | 30992 | 31246 | 31531 | 31802 | 32096 |
Retained Earnings (Accumulated Deficit) | -438 | -5072 | -17977 | -21330 | -21408 | -24600 |
Unrealized Gain (Loss) | -138 | -144 | -338 | 22 | 1 | |
Other Equity, Total | -333 | -535 | -431 | -550 | -986 | -796 |
Total Liabilities & Shareholders’ Equity | 77626 | 79954 | 66416 | 59707 | 62948 | 61165 |
Total Common Shares Outstanding | 738.2 | 722.2 | 629.6 | 591.4 | 578.3 | 558.3 |
Prepaid Expenses | 1156 | 1223 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 21299 | 19099 | 24380 | 19385 | 18520 |
Likvider og Kortsigtede Investeringer | 10566 | 8082 | 12921 | 8037 | 6544 |
Likvider & Lignende | 6112 | 6630 | 11969 | 7989 | 6528 |
Kortsigtede Investeringer | 4454 | 1452 | 952 | 48 | 16 |
Totale Tilgodehavender, Netto | 4423 | 4479 | 4765 | 4895 | 5077 |
Accounts Receivable - Trade, Net | 4423 | 4479 | 4765 | 4895 | 5077 |
Total Inventory | 4017 | 4115 | 4152 | 4086 | 4411 |
Other Current Assets, Total | 2293 | 2423 | 2542 | 2367 | 2488 |
Total Assets | 62539 | 59773 | 64993 | 61165 | 59196 |
Property/Plant/Equipment, Total - Net | 4855 | 4906 | 4982 | 5184 | 5142 |
Goodwill, Net | 14673 | 14676 | 14665 | 14890 | 14897 |
Intangibles, Net | 15947 | 15308 | 14659 | 15182 | 14567 |
Other Long Term Assets, Total | 5765 | 5784 | 6307 | 6524 | 6070 |
Total Current Liabilities | 12869 | 14585 | 14842 | 12184 | 12886 |
Accounts Payable | 1396 | 1277 | 1171 | 1366 | 1403 |
Accrued Expenses | 9917 | 8984 | 9383 | 10731 | 10639 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1556 | 4324 | 4288 | 87 | 844 |
Total Liabilities | 53205 | 51526 | 56776 | 54465 | 58280 |
Total Long Term Debt | 31129 | 28458 | 33291 | 33222 | 36010 |
Long Term Debt | 31129 | 28458 | 33291 | 33222 | 36010 |
Other Liabilities, Total | 9207 | 8483 | 8643 | 9059 | 9384 |
Total Equity | 9334 | 8247 | 8217 | 6700 | 916 |
Common Stock | 31806 | 31877 | 31989 | 32096 | 31247 |
Retained Earnings (Accumulated Deficit) | -21639 | -22762 | -22964 | -24600 | -29568 |
Unrealized Gain (Loss) | 1 | 1 | 0 | 0 | |
Other Equity, Total | -834 | -869 | -808 | -796 | -763 |
Total Liabilities & Shareholders’ Equity | 62539 | 59773 | 64993 | 61165 | 59196 |
Total Common Shares Outstanding | 575.3 | 569.6 | 565 | 558.3 | 534.2 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto indkomst/Startlinje | 7722 | 1979 | 8394 | 7842 | 7264 | 5893 |
Likvider Fra Driftsaktiviteter | 10354 | 11177 | 11296 | 9150 | 10497 | 9261 |
Likvider Fra Driftsaktiviteter | 2105 | 1955 | 1946 | 2206 | 3601 | 3398 |
Deferred Taxes | 183 | -1330 | -363 | -289 | -287 | -453 |
Ikke-Likvide Ting | 343 | 663 | 697 | 122 | 135 | 1617 |
Cash Taxes Paid | 1100 | 1500 | 1900 | 1900 | 1400 | 1900 |
Likvid Rente Betalt | 1300 | 1300 | 1500 | 1300 | 1200 | 1200 |
Ændringer i Driftskapital | 1 | 7910 | 622 | -731 | -216 | -1194 |
Likvider fra Investeringsaktiviteter | -8658 | -4024 | 14339 | 5709 | -5401 | 733 |
Kapitaludgifter | -837 | -664 | -738 | -618 | -608 | -880 |
Andre Investerings-Cash-Flow-Ting, Total | -7821 | -3360 | 15077 | 6327 | -4793 | 1613 |
Likvider fra Financieringsaktiviteter | -2599 | -6594 | -22490 | -15767 | -4867 | -8271 |
Financiering af Cash-Flow-Ting | -284 | -140 | -68 | -42 | -90 | -78 |
Total Cash Dividends Paid | -2998 | -3365 | -3507 | -3509 | -3755 | -4013 |
Udstedelse (Pensionering) af Aktier, Netto | -2910 | -3160 | -17794 | -7702 | -3486 | -4975 |
Udstedelse (Pensionering) af Gæld, Netto | 3593 | 71 | -1121 | -4514 | 2464 | 795 |
Netto Ændring i Likviditet | -903 | 559 | 3145 | -908 | 229 | 1723 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1646 | 2110 | 3994 | 5893 | 1476 |
Cash From Operating Activities | 2104 | 4035 | 6453 | 9261 | 2164 |
Cash From Operating Activities | 841 | 1696 | 2546 | 3398 | 841 |
Deferred Taxes | -91 | -137 | -264 | -453 | -251 |
Non-Cash Items | 79 | 1675 | 1692 | 1617 | 545 |
Changes in Working Capital | -371 | -1309 | -1515 | -1194 | -447 |
Cash From Investing Activities | -319 | 890 | 963 | 733 | -111 |
Capital Expenditures | -166 | -351 | -593 | -880 | -190 |
Other Investing Cash Flow Items, Total | -153 | 1241 | 1556 | 1613 | 79 |
Cash From Financing Activities | -1939 | -4561 | -1713 | -8271 | -3514 |
Financing Cash Flow Items | -52 | -85 | -104 | -78 | -26 |
Total Cash Dividends Paid | -1016 | -2024 | -3023 | -4013 | -1080 |
Issuance (Retirement) of Stock, Net | -871 | -2452 | -3532 | -4975 | -6360 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 4946 | 795 | 3952 |
Net Change in Cash | -154 | 364 | 5703 | 1723 | -1461 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.842 | 47216165 | 1317764 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.459 | 29151093 | 277320 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.4444 | 29073061 | -207866 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9148 | 15564870 | -73750 | 2022-09-30 | LOW |
Capital Research Global Investors | Investment Advisor | 2.3605 | 12605265 | -1490071 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0975 | 11200793 | 502787 | 2022-09-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 1.7297 | 9236530 | 287899 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.5254 | 8145601 | -212030 | 2022-09-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 1.5243 | 8139945 | -45470 | 2022-09-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.333 | 7118039 | -705787 | 2022-12-31 | LOW |
Wells Fargo Advisors | Research Firm | 1.324 | 7070379 | 59546 | 2022-09-30 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 1.2358 | 6599371 | 1971000 | 2022-09-30 | MED |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9481 | 5062588 | -492241 | 2021-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.9186 | 4905395 | 163471 | 2022-09-30 | LOW |
Aristotle Capital Management, LLC | Investment Advisor | 0.9158 | 4890166 | -72128 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.8955 | 4781857 | -445255 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8086 | 4317814 | -103045 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7969 | 4255525 | -170586 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7683 | 4102655 | -193979 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.7668 | 4094846 | 20049 | 2022-09-30 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com GroupHandlende
Månedlkige, aktive klienter
Månedlig investeringsvolumen
Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
Om Amgen
Amgen Inc. er en bioteknologisk virksomhed. Virksomheden opdager, udvikler, fremstiller og leverer forskellige humanmedicinske lægemidler. Virksomheden er aktiv inden for segmentet humane terapeutika. Dens portefølje af markedsførte produkter omfatter Neulasta (pegfilgrastim); erytropoiesis-stimulerende midler (ESA'er), såsom Aranesp (darbepoetin alfa) og EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim) og andre markedsførte produkter, såsom KYPROLIS (carfilzomib), Vectibix (panitumumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) og Corlanor (ivabradin). Virksomheden fokuserer på humane terapeutika til behandling af alvorlige sygdomme inden for onkologi/hematologi, hjerte-kar-sygdomme og neurovidenskab. Blandt virksomhedens produktkandidater i fase III er Erenumab til behandling af episodisk migræne, Aranesp til behandling af myelodysplastiske syndromer, BLINCYTO til behandling af akut lymfoblastær leukæmi og IMLYGIC til behandling af metastatisk melanom.
Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com